Indian Immunologicals Limited (IIL) has set up its second manufacturing facility at Karkapatla, Ranga Reddy district, Telangana with an investment of ₹250 crore.
The unit at Phase III of Genome Valleywill expand IIL’s manufacturing capabilities. It will make vaccines against infectious diseases of humans & animal health formulations. The first phase of human vaccine facility has the capacity to produce 8 million doses of human rabies vaccine. The animal health formulation facility is equipped to produce 300 million tablets, 100 million bolus (animal vaccine), and 20 million vials of injectables, said K Anand Kumar, Deputy Managing Director, IIL, the fully-owned subsidiary of NDDB.